Individualized therapy for metastatic colorectal cancer.
J Intern Med
; 274(1): 1-24, 2013 Jul.
Article
in En
| MEDLINE
| ID: mdl-23527888
ABSTRACT
Systemic therapeutic efficacy is central to determining the outcome of patients with metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive biomarkers to optimize efficacy whilst minimizing toxicity. The integration of a new generation of molecularly targeted drugs into the treatment of CRC, coupled with the development of sophisticated technologies for individual tumours as well as patient molecular profiling, underlines the potential for personalized medicine. In this review, we focus on the latest progress made within the genomic and proteomic fields, concerning predictive biomarkers for individualized therapy in metastatic CRC.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Biomarkers, Tumor
/
Proto-Oncogene Proteins
/
Proteomics
/
Precision Medicine
/
Molecular Targeted Therapy
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Language:
En
Journal:
J Intern Med
Journal subject:
MEDICINA INTERNA
Year:
2013
Document type:
Article
Affiliation country: